Alnylam presents 18-month results from the apollo-b phase 3 study of patisiran in patients with attr amyloidosis with cardiomyopathy

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced new results from an interim analysis of exploratory data from the open-label extension (ole) period of the apollo-b phase 3 study of patisiran, an investigational rnai therapeutic in development for the treatment of transthyretin-mediated (attr) amyloidosis with cardiomyopathy. the results were presented at the annual congress of the heart failure association o.
ALNY Ratings Summary
ALNY Quant Ranking